We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Relief Therapeutics and NeuroRx Seek EUA for COVID-19 Treatment
Relief Therapeutics and NeuroRx Seek EUA for COVID-19 Treatment
Relief Therapeutics and NeuroRx have applied to the FDA for an Emergency Use Authorization (EUA) for RLF-100 (aviptadil) for the treatment of critical COVID-19 patients with respiratory failure.